Psychopharmacologic treatment of borderline personality disorder
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
The best available evidence for psychopharmacologic treatment of borderline personality disorder (BPD) is outlined here. BPD is defined by disturbances in identity and interpersonal functioning, and patients report potential medication treatment targets such as impulsivity, aggression, transient psychotic and dissociative symptoms, and refractory affective instability Few randomized controlled trials of psychopharmacological treatments for BPD have been published recently, although multiple reviews have converged on the effectiveness of specific anticonvulsants, atypical antipsychotic agents, and omega-3 fatty acid supplementation. Stronger evidence exists for medication providing significant improvements in impulsive aggression than in affective or other interpersonal symptoms. Future research strategies will focus on the potential role of neuropeptide agents and medications with greater specificity for 2A serotonin receptors, as well as optimizing concomitant implementation of evidence-based psychotherapy and psychopharmacology, in order to improve BPD patients' overall functioning.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grant, B. F., Chou, S. P., Goldstein, R. B., Huang, B., Stinson, F. S., Saha, T. D., Smith, S. M., Dawson, D. S., Pulay, A. J., Pickering, R. P., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0404 · Cited by 1,618
Social effects of oxytocin in humans: context and person matter
Bartz, J. A., Zaki, J., Bolger, N., & Ochsner, K. N. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.05.002 · Cited by 1,581
Borderline personality disorder
Lieb, K., Zanarini, M. C., Schmahl, C., Linehan, M. M., & Bohus, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16770-6 · Cited by 1,369
Fonagy, P., & Luyten, P. (2009) · Development and Psychopathology · doi:10.1017/s0954579409990198 · Cited by 1,146 · cited 2×
“arious theoretical orientations have converged upon the conceptualization of borderline personality disorder (BPD) as a disturbance in mental representations of self and other, contributing to core difficulties in identity, intimacy, empathy, and self-directed motivation.(1-3) In BPD, this core psychopathology contrib…”
Backgrounddepue, R. A., & morrone-strupinsky, J. V. (2005) · Behavioral and Brain Sciences · doi:10.1017/s0140525x05000063 · Cited by 958
Oxytocin promotes human ethnocentrism
De Dreu, C. K. W., Greer, L. L., Van Kleef, G. A., Shalvi, S., & Handgraaf, M. J. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015316108 · Cited by 870
Feldman, R., Weller, A., Zagoory-Sharon, O., & Levine, A. (2007) · Psychological Science · doi:10.1111/j.1467-9280.2007.02010.x · Cited by 787
Gunderson, J. G. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.37 · Cited by 770 · cited 3×
“As noted above, impulsive aggression is more apt to resolve spontaneously, compared with interpersonal affective symptoms.(18-21) There are no medications approved by the US Food and Drug Administration (FDA) for the treatment of BPD, and very limited data exist for any single medication improving overall BPD severity.”
BackgroundSkodol, A. E., Gunderson, J. G., McGlashan, T. H., Dyck, I. R., Stout, R. L., Bender, D. S., Grilo, C. M., Shea, M. T., Zanarini, M. C., Morey, L. C., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.276 · Cited by 708
Choi-Kain, L. W., & Gunderson, J. G. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07081360 · Cited by 565 · cited 2×
“arious theoretical orientations have converged upon the conceptualization of borderline personality disorder (BPD) as a disturbance in mental representations of self and other, contributing to core difficulties in identity, intimacy, empathy, and self-directed motivation.(1-3) In BPD, this core psychopathology contrib…”
Background
Cited by
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Medications have limited benefits in the management of Borderline Personality Disorder, with atypical antipsychotic agents having the best established efficacy (Ripoll, 2013; Stoffers et al., 2010).”
BackgroundPalhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
“Second, patients with comorbid personality disorders present higher placebo responses (Ripoll, 2013), and in our study, most patients (76”
BackgroundPsychiatric risks for worsened mental health after psychedelic use
Marrocu, A., Kettner, H., Weiss, B., Zeifman, R. J., Erritzoe, D., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241232548 · Cited by 60
“This, as well as a significant need for better treatments (Alvarez-Tomás et al., 2017; Cristea et al., 2017; Ripoll, 2013), has contributed to some questioning whether even these excluded categories could benefit from psychedelic therapy, perhaps especially so if the treatment was to be tailored to…”
BackgroundChung, B. Y., Hensel, S., Schmidinger, I., Bekrater‐Bodmann, R., & Flor, H. (2020) · European Journal of Pain · doi:10.1002/ejp.1567 · Cited by 36
Significance of borderline personality-spectrum symptoms among adolescents with bipolar disorder
Fonseka, T. M., Swampillai, B., Timmins, V., Scavone, A., Mitchell, R., Collinger, K. A., & Goldstein, B. I. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.08.046 · Cited by 18
Metadata
- Authors
- Ripoll, L. H.
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2013-06-30
- Volume
- 15
- Issue
- 2
- Pages
- 213-224
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- OpenAlex
- W197227983
- Cited by
- 54
- References
- 36
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychopharmacologic treatment of borderline personality disorder. https://app.cochat.ai/papers/10.31887/dcns.2013.15.2/lripoll
- The paper
- Ripoll, L. H. (2013). Psychopharmacologic treatment of borderline personality disorder. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2013.15.2/lripoll
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.